The effect of vasopressin nasal spray on intradialytic hypotensio

Not Applicable

• Conditions: Condition 1: End stage renal desease patients who underwent hemodialysis treatment. Condition 2: Intradialytic hypotension.; Chronic kidney disease, stage 5; Other hypotension

• Registration Number: IRCT2015060222540N1
• Lead Sponsor: All costs of this study were be paid by the researcher

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

ESRD patients with known symptomatic episode of intradialytic hypotension in at least 30% of hemodialysis sessions in the 30 days preceding enrollment; Serum sodium levels greater than 140 mEq/L.
Exclusion criteria: History of ischemic heart desease; History of cardiovascular events (MI, CVA, ...); Anemia (HB<10 g/dL); Usage of other treatments for intradialytic hypotension at the same time

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intradialytic Hypotension. Timepoint: Before hemodialysis and 1, 2, 3 ,4 hours after the start of hemodialysis start. Method of measurement: By Mercury sphygmomanometer - A fall in Systolic Blood Pressure by at least 20 mmHg or a decrease in mean arterial pressure by at least 10 mmHg with clinical symptomes of hypotension after onset of hemodialysis.;Saline volume. Timepoint: After intradialytic hypotension occures and needes intervertion. Method of measurement: By the given volume of saline (mL).